Lupin, through its subsidiary Lupin Atlantis Holdings SA (LAHSA), has entered a licensing and supply agreement with Galenicum Health, S.L.U. for finished formulations of injectable Semaglutide, a GLP-1 receptor agonist.
Agreement Details
Under the deal, Galenicum oversees development, manufacturing, and supply. Lupin manages regulatory submissions, approvals, commercialization, and distribution across 23 countries, including Canada, Europe, Southeast Asia, and Latin America.
This partnership positions Lupin to expand its leadership in diabetes care and obesity treatment beyond India.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
"Our partnership with Galenicum marks a strategic milestone in strengthening Lupin's Semaglutide portfolio. As diabetes continues to escalate globally and obesity emerges as a major global health priority, Semaglutide stands out as a critical therapy. This collaboration enables us to capitalize on worldwide growth opportunities in the expanding GLP-1 market. With our extensive commercial presence across Canada, Europe, Southeast Asia, and Latin America, we are positioned to scale access at the right moment—further reinforcing our commitment to delivering high-quality, cost-effective medicines and expanding access to Semaglutide for patients in these regions," said Fabrice Egros, President, Corporate Development, Lupin.
What is Semaglutide?
Semaglutide is a generic form of glucagon-like peptide-1 (GLP-1) that regulates blood sugar and appetite. It is prescribed for adults with Type 2 Diabetes alongside diet and exercise. It also supports long-term weight management in adults with obesity or overweight conditions.
"This partnership is a cornerstone of our strategy to scale high-impact volumes of Semaglutide globally. At Galenicum, we have invested heavily in our GLP-1 development pipeline to meet the surging demand for these life-changing therapies. Our goal is clear: to be a leader in the B2B GLP-1 space, providing our partners with the reliability, scale, competitiveness, and quality required to transform patient care worldwide," said Joaquim Domingo, co-founder of Galenicum.